Replies to post #201551 on Biotech Values

[DewDiligence]

If I recall you thought LLY overpaid for imclone…

I did think that and still do, although this PoV could change with new data derived from IMCL's pipeline.

Bear in mind that IMCL had to separately pay BMY to obtain the North American rights to Erbitux, so the cumulative price LLY paid to acquire IMCL’s assets was somewhat higher than the reported amount.

[DewDiligence]

From a practical standpoint, investing is LLY is very much a bet on the AD programs.